Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02852005 · ClinicalTrials.gov registry record · Phase 1

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
9
Study locations

NCT02852005 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 27 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02852005, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the AIDSVAX B/E vaccine and the MVA/HIV62B vaccine in healthy, HIV-1-uninfected adults who previously received MVA/HIV62B in DNA/MVA or MVA/MVA vaccine regimens in the HVTN 205 study.

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL MVA/HIV62B vaccine
  • BIOLOGICAL AIDSVAX B/E vaccine

Study Locations (9)

New York

  • Columbia P&S CRS - New York
  • University of Rochester Vaccines to Prevent HIV Infection CRS - Rochester

Alabama

  • Alabama CRS - Birmingham

California

  • Bridge HIV CRS - San Francisco

Georgia

  • The Hope Clinic of the Emory Vaccine Center CRS - Decatur

Massachusetts

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS) - Boston

Washington

  • Seattle Vaccine and Prevention CRS - Seattle

Maynas

  • ACSA CRS - Iquitos

Other

  • Barranco CRS - Lima

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2017-01
Est. Completion 2019-10-29
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02852005

The ClinicalTrials.gov registry entry for NCT02852005 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02852005 reports 9 study locations spanning 8 distinct geographic areas - top geographies include New York, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT02852005 about?

NCT02852005 is a clinical study titled "Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205". The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the AIDSVAX B/E vaccine and the MVA/HIV62B vaccine in healthy, HIV-1-uninfected adults who previously received MVA/HIV62B in DNA/MVA or MVA/MVA vaccine regimens in the HVTN 205 study.

What is the current status of trial NCT02852005?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2017-01. Estimated completion is 2019-10-29.

What conditions does trial NCT02852005 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT02852005?

The interventions under investigation include: Placebo (BIOLOGICAL), MVA/HIV62B vaccine (BIOLOGICAL), AIDSVAX B/E vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT02852005?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02852005 being conducted?

This trial has 9 study locations across Alabama, California, Georgia, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.